Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Hepatitis C
Interventions: rosuvastatin, atorvastatin; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Myopathic Conditions
Interventions: cellulose placebo vs. atorvastatin; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypercholesterolemia, Familial, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Aggressive Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Drug · Other · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Denver, Colorado • Seattle, Washington

Conditions: Myopathy, HMG COA Reductase Inhibitor Adverse Reaction, Hypercholesterolemia
Interventions: ubiquinol, placebo, statin; Dietary Supplement · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia
Interventions: PPAR alpha, atorvastatin, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 28
States / cities: Fayetteville, Arkansas • Stockton, California • Highlands Ranch, Colorado + 25 more

Conditions: Diabetes Melliuts, Type 2
Interventions: Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more

Conditions: Stroke
Interventions: Anti-platelets and statin, alteplase, intra arterial intervention; Drug · Procedure
Lead sponsor: Jacobs Neurological Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Vaccine Response
Interventions: Atorvastatin, Quadrivalent seasonal influenza vaccine; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, Statin, PF-04950615 (RN316), Satin; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 38
States / cities: Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more

Conditions: Atherosclerosis
Interventions: Atorvastatin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HDL Cholesterol
Interventions: Simvastatin, Atorvastatin 80 mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Mitochondrial Diseases
Interventions: Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo Oral Tablet; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 35 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Kansas City, Kansas • Greenville, North Carolina

Conditions: Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions: Atorvastatin Calcium; Drug
Lead sponsor: Philip Binkley; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Osteoporosis
Interventions: SB-751689; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 65 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Coronary Atherosclerosis
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 97
States / cities: Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more

Conditions: Kawasaki Disease
Interventions: Atorvastatin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 2 Years to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Venous Thromboembolism
Interventions: Atorvastatin, Anticoagulation Therapy; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Nonalcoholic Steatohepatitis
Interventions: Obeticholic Acid, Atorvastatin, Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 22
States / cities: Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more

Conditions: Coronary Atherosclerosis
Interventions: Placebo, TriLipix; Drug
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Participants
Interventions: TMC435, Atorvastatin, Simvastatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Heart Failure, Congestive
Interventions: atorvastatin, placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Is Myopathy Part of Statin Therapy (IMPOSTER-16)

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS

A Study in People With High Cholesterol

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

Systems Biological Assessment of Statin Effect on Vaccine Responses

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions

Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

CRESTOR Athero Imaging Head to Head IVUS Study

Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

Statin Use in Patients With Acute VTE

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit